drugset / Trial / NCT00203138

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

NCT00203138

Phase 3 Completed 306 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.

Timeline

Start
2004-06
Primary completion
2006-11
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule

Indications